Sanofi Adds To Immunology Pipeline In Collaboration With Recludix

 
• By Joseph Haas

French pharma gets global rights at the start of Phase II for the US biotech’s preclinical program for inhibiting the STAT6 protein in respiratory and dermatologic disorders.

Sanofi building
Sanofi is betting that Recludix's approach to STAT protein inhibition succeeds

More from Deals

More from Business